Drug Profile
Leukocyte cell therapy - Enlivex Therapeutics
Alternative Names: Allocetra; Allocetra-OTS; OTS-AllocetraLatest Information Update: 19 Apr 2024
Price :
$50
*
At a glance
- Originator Hadassah Medical Organization
- Developer Enlivex Therapeutics; Hadassah Medical Organization
- Class Antineoplastics; Cell therapies; Immunotherapies
- Mechanism of Action Cell replacements; Leukocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Graft-versus-host disease; Inflammation; Lung disorders; Multiple organ failure; SARS-CoV-2 acute respiratory disease
- Phase I/II Osteoarthritis; Peritoneal cancer; Solid tumours
- Preclinical Mesothelioma
- No development reported Crohn's disease; Gout; Multiple sclerosis; Rheumatoid arthritis; Transplant rejection
- Discontinued COVID 2019 infections
Most Recent Events
- 17 Apr 2024 Danish Regulatory Agency approves clinical trial application for Leukocyte cell therapy for phase I/II trial in osteoarthritis
- 11 Apr 2024 Efficacy and adverse events data from a phase II trial in Multiple organ failure released by Enlivex Therapeutics
- 11 Apr 2024 Enlivex Therapeutics plans a clinical trial for Multiple organ failure (IV, Infusion)